Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Monoclonal and polyclonal circulating plasma cells (CPCs) are linked to disease spread in multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

MTMarco TalaricoVSVincenza SolliBTBarbara Taurisano

Discussion

Loading...

Member takes

Overview

Study demonstrates higher genomic risk and unfavorable outcomes in multiple myeloma patients with circulating plasma cells, suggesting aggressive disease progression.

Key Points

  • Detectable circulating plasma cells in 80% of newly diagnosed multiple myeloma patients were linked to worse clinical features.
  • Higher frequency of genomic risk profiles observed in patients with monoclonal circulating plasma cells compared to polyclonal.
  • Analysis of genomic profiles combined with diffusion-weighted and PET imaging assessed tumor dissemination in the bone marrow.
  • Presence of circulating plasma cells indicates a significant correlation with increased risk of relapse and systemic disease spread.

Cite This Study

Talarico et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1f1https://doi.org/10.1182/blood-2025-3918
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Quantification of circulating plasma cells at diagnosis can identify functional high risk multiple myeloma patients2025
  2. 2Phenotypic evolution of circulating tumor plasma cells across MGUS, SMM and multiple myeloma2025
  3. 3Circulating tumor plasma cells as an independent prognostic marker in newly diagnosed multiple myeloma: Clinical correlation and immunophenotypic insights2025
  4. 4Multiple myeloma with ≥1% circulating plasma cells in peripheral blood has a poor prognosis2025
  5. 5Biology of circulating tumor cells (CTCs) in multiple myeloma (MM): Comparative transcriptomic profiling reveals egression-associated changes related to CTC burden2025